Mindwalk Holdings Corp. · NASDAQ:HYFT
Mindwalk — ImmunoPrecise Antibodies — FY2024 Earnings Presentation
16 slides from Mindwalk's earnings presentation, Jul 29, 2024
Slide 1: Fiscal Year 2024 Earnings Presentation
Fiscal year 2024 Earnings Presentation July 29, 2024 | ir.ipatherapeutics.com | NASDAQ: IPA
Slide 2: Disclosures
Disclosures Disclaimer This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilitie
Slide 3: Fiscal Year 2024 Business Update
Fiscal Year 2024 Year End Earnings Call Fiscal Year 2024 Business Update
Slide 4: Market Highlights
Fiscal Year 2024 Year End Earnings Call Market Highlights Strategically built – foresight for the future Amid industry change, IPA strengthened its market position End-to-end, full continuum offering > Highly nimble and adaptable to client and market needs Wet Lab LENSai TM Integrated Intelligence T
Slide 5: Business Highlights
Fiscal Year 2024 Year End Earnings Call Business Highlights Significant strides in strategic initiatives positioning us for accelerated growth Strong Revenue Innovative Strategic Growth and Product Collaborations Financial Launches Prudence Innovation + Operational Excellence Industry Leadership Awa
Slide 6: Strong growth continued – quarterly and annually
Fiscal Year 2024 Year End Earnings Call Driven by mission and strategy Strong growth continued – quarterly and annually Fiscal year end 2024 Q4 2024 19% YOY Q3 2024 $24.5M Total Revenue Five back-to-back record revenue quarters Q2 2024 Q1 2024 Q4 2023 ir.ipatherapeutics.com | NASDAQ:IPA ©2024 Immuno
Slide 7: Significant strides in our strategic initiatives
Fiscal Year 2024 Year End Earnings Call Innovation + Expansion Significant strides in our strategic initiatives: Highlighting strong performance and ability to drive innovation and efficiency across all operations Launched BioStrand’s Currently onboarding LENSai on 2024 Awards, InterSystems LENSai F
Slide 8: Revenue expansion through BioStrand's advanced LENSai technology access models
Fiscal Year 2024 Year End Earnings Call Revenue expansion through BioStrand’s advanced LENSai technology access models API Revenue SAAS Capability Expansion Early Adopter Portal – subscriptions generation – LENSai BioIntelligence Cloud now and into the future Fee-for-service Partnership End-to-end i
Slide 9: Summary
Fiscal Year 2024 Year End Earnings Call Summary Looking ahead we anticipate continued expansion and progress in FY 25 • Strong operational performance • Successful execution of our strategic initiatives • Focused liquidity management • Robust demand for our products and services ir.ipatherapeutics.c
Slide 10: Fiscal Year 2024 Financial Update
Fiscal Year 2024 Year End Earnings Call Fiscal Year 2024 Financial Update
Slide 11: Continued record quarter revenue achieved
Fiscal Year 2024 Year End Earnings Call Continued record quarter revenue achieved $7.0 M $6.2 M $6.2 M $6.5 M $6.0 M $5.7 M $5.6 M $5.2 M $5.2 M $5.2 M $5.0 M $4.7 M $4.6 M $4.7 M $4.8 M $4.0 M $3.0 M $2.0 M $1.0 M $0.0 M Q1 Q2 Q3 Q4 FY24 FY23 FY22 All values listed in CAD. ir.ipatherapeutics.com |
Slide 12: Fiscal year 2024 revenue of $24.5M, 19% growth
Fiscal Year 2024 Year End Earnings Call Fiscal year 2024 revenue of $24.5M, 19% growth $25 M $25 M FY22 BioStrand LENSai acquisition to enable revenue and gross margin growth rates higher than historical wet lab $21 M $20 M $19 M $18 M $15 M $14 M $11.5 M $11.6 M $12.1 M $11 M $11.0 M $10 M $8.0 M $
Slide 13: Year over year reduction in operating expenses
Fiscal Year 2024 Year End Earnings Call Year over year reduction in operating expenses Spend reflects focus on LENSai commercialization and expense management Research & Development Sales & Marketing General & Administrative $16.0 M $4.0 M $18.0 M $14.1 M $14.0 M $3.5 M $3.6 M $17.0 M $12.0 M $3.5 M
Slide 14: Net Loss of $27.2M, ($1.06) per share
Fiscal Year 2024 Year End Earnings Call Net Loss of $27.2M, equivalent to ($1.06) per share (basic & diluted) Impairment expense of $15M in FY24 vs $2.5M in FY23 Net Loss Earnings Per Share -$26.2 M -1.05 -$26.4 M -$26.6 M -1.06 -$26.6 M -1.06 -1.07 -$27.2 M -$26.8 M -$27.0 M -1.07 -$27.2 M -$27.4 M
Slide 15: Cash of $3.5M with reduced cash burn
Fiscal Year 2024 Year End Earnings Call Cash of $3.5M with reduced cash burn FY24 Cash Burn Breakdown FY24 $3.0 M $2.0 M $2.4 M Revenue $24.5M $1.0 M with gross profit $0.0 M -$1.0 M margin of 49%, from three CRO sites used to -$2.0 M -$1.4 M fund AI R&D to transform drug -$3.0 M discovery and devel
Slide 16: Q&A FY 2024 Year End Earnings Call
Q&A FY 2024 Year End Earnings Call The HUB of July 29, 2024 | ir.ipatherapeutics.com | NASDAQ: IPA TSXV: IPA Biotherapeutic ©2024 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of ImmunoPrecise
ImmunoPrecise Antibodies — FY2024 Earnings Presentation on 6ix